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Abstract 
Objectives: Hypertrophy has been shown to be associated with arrhythmias which can be 
caused by abnormal remodeling of the Kv4-family of transient potassium channels. Inhibitors 
of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) have recently been shown to 
exert pleiotropic protective effects in cardiovascular diseases, including anti-arrhythmias. It is 
hypothesized that remodeling of Kv4.3 occurs in rat hypertrophied cardiomyocytes and is 
regulated by simvastatin.  
Methods: Male Sprague-Dawley rats and neonatal rat ventricular myocytes (NRVMs) un-
derwent abdominal aortic banding (AAB) for 7 weeks and angiotensin II (AngII) treatment, 
respectively, to induce cardiac hypertrophy. Kv4.3 expression by NRVMs and myocardium 
(subepicardial and subendocardial) in the left ventricle was measured. The transient outward 
potassium current (Ito) of NRVMs was recorded using a whole-cell patch-clamp method.  
Results: Expression of the Kv4.3 transcript and protein was significantly reduced in myo-
cardium (subepicardial and subendocardial) in the left ventricle and in NRVMs. Simvastatin 
partially prevented the reduction of Kv4.3 expression in NRVMs and subepicardial myocar-
dium but not in the subendocardial myocardium. Hypertrophied NRVMs exhibited a signifi-
cant reduction in the Ito current and this effect was partially reversed by simvastatin.  
Conclusions: Simvastatin alleviated the reduction of Kv4.3 expression, Ito currents in hy-
pertrophied NRVMs and alleviated the reduced Kv4.3 expression in subepicardial myocar-
dium from the hypertrophied left ventricle. It can be speculated that among the pleiotropic 
effects of simvastatin, the anti-arrhythmia effect is partly mediated by its effect on Kv4.3. 
Key words: Potassium channels; Kv4.3; arrhythmias; hydroxymethylglutaryl-CoA reductase in-
hibitors; hypertrophy. 
Introduction 
Sudden  cardiac  death  is  commonly  caused  by 
ventricular  tachyarrhythmias  [1].  Studies  have  indi-
cated several alterations in cellular electrophysiology 
in  hypertrophied  myocardium,  including  prolonga-
tion of the action potential duration [2], which may 
lead  to  ventricular  arrhythmias.  Previous  investiga-
tions have highlighted the importance of potassium 
channel remodeling in the prolongation of action po-
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tential  durations  in  models  of  hypertrophy  [3,  4]. 
Furthermore,  it  is  believed  that  suppression  of  re-
polarizing  potassium  currents  leading  to  action  po-
tential prolongation provides an explanation for QT 
prolongation/dispersion,  thereby  accounting  for  a 
major mechanism of arrhythmogenesis [1]. Potassium 
channels include diverse classes of ion channels in the 
heart [5]. The transient outward potassium currents 
(Ito), which can be classified as voltage-gated currents, 
contribute to  cardiac action potential duration, Ca2+ 
handling,  contractility  and  hypertrophy.  Cardiac 
disease is invariably associated with Ito and changes in 
Ito have been linked to a long QT-interval and Bru-
gada  syndrome  arrhythmias  [6-11].  Kv4.3,  which  is 
the  pore-forming  subunit  of  Ito,  is  uniformly  ex-
pressed  in  the  ventricle  [12,  13].  Expression  of  the 
Kv4.3 gene is decreased by cardiac hypertrophy in-
duced by congestive heart failure in humans [14, 15] 
and  downregulated  by  cardiac  hypertrophy  in  rats 
[1].  
Simvastatin,  one  of  the  hydroxymethylglutaryl 
coenzyme  A  reductase  inhibitors  (statins),  has  been 
shown  to  reduce  cardiovascular-related  morbidity 
and mortality in clinical trials independent of its cho-
lesterol-lowering  function  [16,  17]  and  has  been 
demonstrated to impact cardiac remodeling, includ-
ing hypertrophy [18-20]. Interestingly, recent studies 
have  also  shown  that  simvastatin  decreases  ar-
rhythmogenesis  [21-24]  and  the  potential  link  be-
tween  Kv4.3  and  simvastatin  is  suggested  by  these 
studies  of  hypertrophy.  However,  little  is  known 
about the effect of simvastatin on cardiac Kv4.3 ex-
pression. Therefore, modulation of Kv4.3 expression 
by simvastatin was investigated in this study using 
the  abdominal  aortic  banding  (AAB)  rat  model  of 
cardiac  hypertrophy.  Specifically,  the  effects  of 
simvastatin on Kv4.3 expression were investigated in 
the subepicardial and subendocardial myocardium of 
AAB rats. Furthermore, the effects of simvastatin on 
Kv4.3  expression  and  Ito  in  neonatal  rat  ventricular 
myocytes  (NRVMs)  were  investigated.  It  was  ob-
served  that  simvastatin  partially  suppressed  the  re-
duction in Kv4.3 expression in hypertrophied NRVMs 
and  the  subepicardial  myocardium,  but  not  in  the 
subendocardial myocardium, with an associated re-
covery in Ito.  
Materials and methods  
AAB surgical procedures 
Male Sprague-Dawley (SD) rats were purchased 
from the Animal Center of the Fourth Military Medi-
cal  University  (FMMU).  The  experimental  protocol 
was  approved  by  the  Institutional  Care  and  Use 
Committee  of  the  FMMU,  which  conforms  to  the 
Guidelines for the Care and Use of Laboratory Ani-
mals  of  the  US  National  Institutes  of  Health  (NIH 
publication No. 85-23, revised 1996). Simvastatin was 
purchased  from  Merck,  Sharp  &  Dohme  Inc.  Other 
chemicals were of laboratory grade.  
Rats (180-220 g; aged 9-12 weeks) were divided 
into  four  groups  (n  =  10):  Sham  group,  where  rats 
underwent surgery without constriction of the aorta; 
Sham  group  treated  with  simvastatin  (40  mg/kg 
*day)  (SS  group);  abdominal  aortic  banding  (AAB 
group); and AAB rats treated with simvastatin (AABS 
group). All rats were anesthetized with an intraperi-
toneal  injection  of  pentobarbital  sodium  45  mg/kg. 
AAB was performed as previously described [25] with 
minor  modifications.  In  brief,  after  anesthetization, 
rats were restrained and a midline abdominal incision 
was  performed  under  sterile  conditions.  The  ab-
dominal aorta above the renal arteries was dissected 
away.  A  ligature  (4-0  silk  suture)  was  positioned 
around  the  aorta  and  a  blunted  22  gauge  needle, 
which  was  then  withdrawn,  leading  to  constriction 
(approximately 50%) of the aorta. After surgery, each 
rat received penicillin 30 kU intramuscularly as anti-
biotic  therapy.  Simvastatin  was  dissolved  in  0.9% 
NaCl solution. All rats received placebo (0.9% NaCl 
solution) or simvastatin by intragastric administration 
every day for 7 weeks after surgery. 
2-D echocardiography, hemodynamic and left 
ventricular-weight index (LVWI) measure-
ments 
Echocardiograms were performed kindly by Dr. 
Yunyan  Duan  (Department  of  Ultrasonography,  Xi-
jing  hospital,  Xi’an,  China),  as  previously  reported 
[26, 27]. In brief, rats were anesthetized as previously 
described. A 2-D axis view of the left ventricle was 
obtained with a 7.5-MHz transducer and the M-mode 
tracings were then recorded to measure the indexes of 
left ventricle: left ventricular posterior wall thickness 
of diastasis (LVPWTd), interventricular septal thick-
ness of diastasis (IVSTd) and left ventricular fractional 
shortening (LVFS).  
For  hemodynamic  measurements,  the  right  ca-
rotid  of  anesthetized  rats  was  cannulated  with  a 
catheter connected to a microtip pressure transducer 
(Biological  Instruments,  ChengDu,  China).  The 
transducer  was  connected  to  a  recording  system 
(Rm6280C, Biological Instruments, ChengDu, China). 
The catheter was then advanced into the left ventricle 
for measuring the left ventricular end-systolic pres-
sure  (LVESP)  and  the  left  ventricular  end-diastolic 
pressure (LVEDP) [28].  Int. J. Biol. Sci. 2012, 8 
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Blood samples were collected and rats were sac-
rificed  by  cervical  vertebrae  dislocation.  The  hearts 
were removed and the left ventricles were dissected. 
The left ventricle was weighed and divided by body 
weight in order to calculate the LVWI. 
Triglyceride (TG) and total cholesterol (TC) 
measurement 
Serum was isolated from blood samples by cen-
trifugation  for  measurement  of  TG  and  TC  levels 
(performed by Yan Xu at the Department of Clinical 
Laboratory,  Xijing  Hospital,  FMMU,  Xian,  Shaanxi, 
China).  
 Cell culture and treatment 
Monolayer cultures of NRVMs were prepared as 
described  previously  [29].  Ventricular  myocardium 
from neonatal SD rats (aged 1 d, FMMU) were  ho-
mogenized and dissociated with collagenase II. The 
cell suspension was plated onto a 10 cm dish for 1 h, 
allowing enrichment for cardiomyocytes by differen-
tial adhesion. The supernatant was then plated on to 
new dishes with Dulbecco’s modified Eagle’s medium 
(DMEM,  Gibco-BRL)  containing  1%  penicil-
lin-streptomycin  and  10%  fetal  bovine  serum  (FBS) 
under  5%  CO2  at  37°C.  The  remaining  fibroblasts 
were  minimized  by  the  addition  of  10  µM 
5-bromodeoxyuridine for 24 h. NRVMs were divided 
into  four  groups:  control  (Ctrl  group);  Ctrl  treated 
with simvastatin (Ctrl+Sim group); cells treated with 
AngII  (AngII  group);  and  cells  pretreated  with 
simvastatin before being incubated with AngII (An-
gII+Sim group). Cells were treated with simvastatin 
and  Ang  II  according  as  previously  described  [30]. 
Briefly, after 24 h serum starvation, cells were treated 
with 1 µM simvastatin (sodium salt, MERCK Biosci-
ences) in treatment medium (DMEM containing 0.5% 
serum). AngII (ALEXIS BIOCHEMICALS) was added 
to a final concentration of 100 nM 12 h after the addi-
tion of simvastatin. Cells were then incubated in the 
presence of both drugs for a further 24 h [30].  
Measurement of NRVMs protein content 
NRVMs were trypsinized, counted using a cell 
counting chamber and then lysed. Cell lysates were 
prepared  to  determine  protein  content  by  Bradford 
protein assay. The protein content of cells was deter-
mined by dividing the total amount of protein by the 
number of cells. 
Electrophysiology 
Whole-cell  patch-clamp  recordings  were  per-
formed at room temperature as previously described 
(Axon  Instruments)  [31].  The  intracellular  solution 
contained potassium glutamate 130 mM, KCl 9 mM, 
NaCl  10  mM,  MgCl2  0.5  mM  MgATP  5  mM  and 
HEPES  10  mM  (pH  7.2).  The  extracellular  solution 
contained  NaCl  138  mM,  KCl  4  mM,  CaCl2  2mM, 
MgCl2 1 mM, Na2HPO4 0.33 mM, HEPES 10 mM and 
glucose 10 mM (pH7.4). The liquid junction potential 
between  the  pipette  solution  and  the  bath  solution 
was estimated to be approximately 10 mV, as reported 
previously [32]. 
Immunofluorescence staining of NRVMs 
Immunoconfocal fluorescence was used to assess 
Kv4.3  expression  in  NRVMs.  Cultured  cells  were 
fixed and permeabilized with 0.5% TritonX-100. After 
washing with phosphate-buffered saline (PBS), cells 
were  preincubated  with  1%  bovine  serum  albumin 
(BSA) to block non-specific binding. Monoclonal an-
ti-cardiac α-actin antibody (1:500; Sigma) was used to 
identify cardiac myocytes. Cells were then incubated 
with  fluorescein  isothiocyanate  (FITC)-conjugated 
goat  anti-mouse  IgG  (1:100;  BD  Pharmingen).  For 
double  immunolabeling,  secondary  labeling  was 
performed  with  1:500  anti-potassium-channel  Kv4.3 
antibody followed by Cy3-conjugated goat anti-rabbit 
IgG (1:100; BD Pharmingen). Cells were then treated 
with  4,6-Diamidino-2-phenylindole  dihydrochloride 
hydrate (DAPI) to stain cell nuclei and analyzed by 
fluorescence  microscopy  (Department  of  Anatomy, 
FMMU).  
Western blots  
Each  sample  of  left  ventricular  tissue  was  di-
vided  into  subepicardial  and  subendocardial  myo-
cardium  from  the  equivalent  region  of  the  animal 
heart. NRVMs and tissue samples were lysed in lysis 
buffer  containing  50  mM  Tris,  150  mM  NaCl,  1% 
Nonidet  P-40,  0.25%  superoxide  dismutase,  1  mM 
EDTA, 1 mM NaF, 1 mM Na3VO3 and 1 mM phenyl-
methylsulphonyl fluoride and included a proteinase 
inhibitor cocktail (Roche). Samples were evaluated by 
SDS-PAGE. Briefly, the total protein of the samples 
was  determined  before  being  subjected  to  poly-
acrylamide gel electrophoresis and being transferred 
to nitrocellulose (NC) membrane. The NC membrane 
was immunoblotted with anti-Kv4.3 antibody (Sigma; 
1:1,000), and anti-GAPDH antibody (Sigma; 1:10,000). 
GAPDH protein expression served as a loading con-
trol. Bands were evaluated by densitometry using the 
Odyssey infrared imaging system (LI-COR). 
Quantitative real-time RT-PCR 
Total  RNA  from  NRVMs,  subepicardial  and 
subendocardial  regions  of  the  ventricle  tissue  was 
extracted with TRIzol Reagent (Invitrogen). RNA was Int. J. Biol. Sci. 2012, 8 
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quantified sectrophotometrically at 260 nm. A 20  µl 
reaction  mixture  (Invitrogen)  was  used  for  reverse 
transcription. The reverse transcription products were 
then  used  as  templates  for  PCR  with  gene-specific 
primers  according  to  previously  reported  methods 
[32, 33] (Table 1). Real-time PCR was performed using 
the  7500  Sequence  Detector  Real-Time  PCR  System 
(Applied  Biosystems).  Cycling  conditions  were  as 
follows: 10 min at 95°C as an initial step, 15 sec at 95°C 
and 1 min at 60°C for 40 cycles. Fluorescence signals 
of genes were recorded during the elongation phase 
of each PCR cycle. Melting curve analysis was used to 
confirm the amplification specificity. GAPDH expres-
sion  served  as  the  internal  control.  Each  gene  was 
quantified in duplicate. Real-time PCR data were an-
alyzed  by  the  comparative  CT  method  as  reported 
[34]. 
Calcineurin phosphatase activity assay 
Calcineurin phosphatase activity was measured 
by  the  dephosphorylation  rate  of  a  synthetic  phos-
phopeptide  substrate  using  a  calcineurin  assay  kit 
(Enzo  Life  Sciences  International)  according  to  the 
instructions provided by the manufacturer. The level 
of released free phosphate was detected colorimetri-
cally at 620 nm using a plate reader.  
Statistical analysis 
Data are presented as the mean ± SEM. One-way 
ANOVA was used for statistical analysis and P<0.05 
was considered statistically significant. 
Results 
Effects of simvastatin on ventricular hyper-
trophy 
In this study, AAB caused cardiac left ventricular 
hypertrophy in vivo 7 weeks after surgery (Fig. 1 and 
Table 2). The LVWI was significantly increased (46 %) 
in the AAB group. Compared with the sham group, 
the LVPWTd and IVSTd in the AAB group were in-
creased  by  42%  and  49%,  respectively.  Compared 
with the AAB group, application of simvastatin de-
creased the LVWI, LVPWTd and IVSTd by 20%, 14.7% 
and 20%, respectively.  
In the AAB and AABS group, atrial natriuretic 
peptide (ANP) mRNA levels in subendocardial and 
subepicardial  myocardium  were  increased  signifi-
cantly compared with the sham group. In the AABS 
group, the ANP mRNA levels were decreased com-
pared with the AAB group. No significant difference 
in ANP mRNA was observed between the sham and 
SS groups (Fig. 2A). 
The  protein  content  per  cell  in  AngII-treated 
NRVMs  was  increased  by  34%  compared  with  the 
control  group.  The  increased  protein  content  was 
partially  reversed  by  12%  in  the  AngII+Sim  group 
compared with the AngII group (Fig. 3B). No signifi-
cant  difference  in  protein  content  per  cell  was  ob-
served between the control group and the Ctrl+Sim 
group.  Furthermore,  pretreatment  with  simvastatin 
inhibited the AngII induced increases in ANP mRNA 
expression, which is a genetic marker of cardiac hy-
pertrophy, in NRVMs (Fig. 3A).  
Effects of simvastatin on lipid profiles (TC, 
TG), LVESP and LVEDP  
In  this  study,  no  significant  differences  were 
observed in blood TG and TC levels among all groups 
of  animals  studied  (Fig.  2B).  LVEDP  and  LVESP 
measurements are shown in Fig. 2C and Fig. 2D. In 
the AAB group, LVESP and LVEDP were increased by 
19% and 81% respectively compared with the sham 
group. Interestingly, LVEDP, but not LVESP was sig-
nificantly reduced by 27% in the AABS group com-
pared with  the AAB group. In accordance with the 
prior study [35], simvastatin-treated rats exhibited a 
reduction  in  LVWI  and  a  significant  reduction  in 
LVEDP, which suggests that simvastatin has benefi-
cial hemodynamic effects.  
Effects of simvastatin on Kv4.3 expression 
In  the  AAB  group,  Kv4.3  protein  levels  were 
consistently  reduced  in  subendocardial  and  subepi-
cardial  myocardium  (by  47%  in  both  groups)  com-
pared with the sham group. Compared with the AAB 
group,  the  reduction  in  subepicardial  myocardium 
Kv4.3 expression appeared to be partially reversed by 
40% in the AABS group. However, there was no sig-
nificant  difference  in  subendocardial  myocardium 
Kv4.3  expression  between  AAB  and  AABS  groups 
(Fig. 4).  
 
Table 1. Primers for real-time RT-PCR 
Gene  Sense 5’-3’  Antisense 5’-3’ 
Kv4.3  CCACGAGTTTATTGATGAGCAGAT  TGTTTTGCAGTTTGGTCTCAGTC 
ANP  AGTGCGGTGTCCAACACAGAT  TTCTCCTCCAGGTGGTCTAGCA 
GAPDH  TGCACCACCAACTGCTTAG  GATGCAGGGATGATGTTC Int. J. Biol. Sci. 2012, 8 
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Table 2. Comparison of left ventricular hypertrophy among four groups. 
  LVWI 
g/kg 
LVPWTd 
mm 
IVSTd 
mm 
LVFS 
% 
Sham  2.235±0.081  0.1415±0.0205  0.1600±0.0159  58.98±11.75 
SS  2.229±0.084  0.1352±0.0233  0.1638±0.0154  67.33±6.19 
AAB  3.269±0.066*   0.2007±0.0349*   0.2377±0.0255*   44.06±10.77*  
AABS  2.631±0.168# *   0.1712±0.0175# *   0.1907±0.0067# *   56.61±6.31# *  
Left ventricular profile in rats from different groups. Data are expressed as the mean ± SEM, n = 10. * P<0.05 vs. Sham group; # P<0.05 vs. 
AAB group. 
 
 
 
 
Figure 1. Echocardiograms showing the vascular and left ventricular profile. Panel A, representative cardiac dilatation. Panel B, repre-
sentative abdominal aortic banding vascular ultrasound imaging. Color Doppler flow and narrow frequency spectrum image of AAB 
indicating angiostegnosis and accelerating blood flow. Panel C, representative echocardiographic M-mode images. All images shown were 
obtained in the rat. Int. J. Biol. Sci. 2012, 8 
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Figure 2. Bar graphs showing ANP mRNA expression, TC, TG, LVESP and LVEDP. Panel A, mRNA expression of ANP in the left ven-
tricle. Panel B, lipid profile (including TC and TG) from blood samples. Panel C and D, LVESP and LVEDP. All results shown were obtained 
in the rat. Data are expressed as the mean ± SEM, n = 10. * P<0.05 vs. Sham group; # P<0.05 vs. AAB group. EPI, subepicardial myo-
cardium; ENDO, subendocardial myocardium.  
 
 
 
 
Figure 3. Bar graphs showing ANP mRNA expression and protein per cell in NRVMs. Data are expressed as the mean±SEM, n = 3. * 
P<0.05 vs. Ctrl group; # P<0.05 vs. AngII group.  
 
 
 
In the AAB group, the Kv4.3 mRNA levels in the 
subepicardial and subendocardial myocardium were 
significantly reduced by 90% and 92%, respectively, 
compared with the sham group (Fig. 5A). Compared 
with the AAB group, a 4-fold increase in Kv4.3 mRNA 
was  observed  in  subepicardial  myocardium  in  the 
AABS group. Interestingly, no significant difference 
was  detected  in  the  Kv4.3  levels  in  subendocardial 
myocardium in the AABS group compared with the 
AAB group (Fig. 5A). Int. J. Biol. Sci. 2012, 8 
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Figure 4. Representative Western blots (Panel A) and relative bar 
graphs (Panel B) showing alterations in Kv4.3 expression in the rat 
left  ventricle.  The  band  intensities  of  Kv4.3  were  normalized 
against that of GAPDH. Data are expressed as the mean ± SEM, n 
= 10. * P<0.05 vs. Sham; # P<0.05 vs. AAB. EPI, subepicardial 
myocardium; ENDO, subendocardial myocardium. 
 
Figure 5. Real-time RT-PCR bar graphs showing alterations of 
relative Kv4.3 mRNA expression in the rat left ventricle and in 
NRVMs. Panel A shows the relative mRNA expression of Kv4.3 in 
the rat left ventricle. Data are expressed as the mean±SEM, n = 10. 
* P<0.05  vs.  Sham  of  respective  group;  # P<0.05  vs.  AAB  of 
respective groups. Panel B represents the relative expression of 
Kv4.3 mRNA in NRVMs. Data are expressed as the mean ± SEM, n 
=  3.  * P<0.05 vs.  Ctrl  group;  # P<0.05 vs.  AngII  group.  EPI, 
subepicardial myocardium; ENDO, subendocardial myocardium.  
Furthermore, Kv4.3 protein and mRNA expres-
sion was detected in NRVMs. The protein and mRNA 
expression of Kv4.3 in the AngII group was signifi-
cantly decreased by 39% and 67%, respectively, com-
pared with control group. Pretreatment with simvas-
tatin partially suppressed the reduction in Kv4.3 pro-
tein and mRNA expression by 86% and 48% respec-
tively compared with the AngII group (Fig. 6 and Fig. 
5,  both  B  panels).  Immunofluorescence  staining  of 
NRVMs also showed that the reduction in Kv4.3 pro-
tein expression was reversed in the AngII+Sim group 
compared with the AngII group (Fig. 7). 
 
 
Figure 6. Representative Western blots (Panel A) and relative bar 
graphs (Panel B) showing alterations of Kv4.3 in NRVMs. Data are 
expressed as the mean ± SEM, n = 3. * P<0.05 vs. Ctrl group; # 
P<0.05 vs. AngII group.  
 
Effects of simvastatin on Ito in NRVMs 
Simvastatin  has  been  reported  to  significantly 
reduce  vulnerability  to  ventricular  fibrillation  and 
shortens the duration of ventricular tachycardia [23, 
24].  However,  the  effects  of  simvastatin  on  electro-
physiology remodeling in hypertrophied heart are not 
fully understood. Therefore, the effects of simvastatin 
on Ito in NRVMs were investigated in this study.  
Following the blockade of INa and ICa by TTX and 
CdCl2,  the  outward  K+  current  densities  were  rec-
orded (Fig. 8A and Fig. 8B). Ito was quantified as the 
difference in the peak current minus Isus, which was 
recorded at the end of the 500-ms voltage step [32]. Int. J. Biol. Sci. 2012, 8 
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AngII suppressed Ito density at voltages ranging from 
+20 to +60 mV compared with control (Fig. 8A, 8B, 8C 
and 8D). At +60 mV, Ito was decreased by 59% from 
11.85 ± 0.75 pA/pF in the Ctrl group to 4.91 ± 0.67 
pA/pF  in  the  AngII  group.  Simvastatin  partially 
prevented AngII induced Ito suppression at voltages 
ranging from +40 to +60 mV. At +60 mV, simvastatin 
reversed  Ito  by  48%  from  4.91  ±  0.67  pA/pF  in  the 
AngII group to 7.26 ± 0.97 pA/pF in the AngII+Sim 
group.  Simvastatin  alone  had  no  effect  on Ito  com-
pared with the control group (Fig. 8E and 8F). 
These  data  suggest  that  simvastatin  alleviated 
Kv4.3 downregulation and Ito current suppression in 
hypertrophied NRVMs.  
Calcineurin activity 
The  data  obtained  in  this  study  revealed  that 
simvastatin  reversed  Kv4.3  downregulation  in  the 
subepicardial myocardium but not the subendocardi-
al myocardium. However, the molecular mechanisms 
of this effect remain to be elucidated. Previous study 
has linked calcineurin with changes in a variety of ion 
channels  although  the  therapeutic  potential  of  tar-
geting  calcineurin  for  correcting  cardiac  electrical 
disturbance has not yet been formulated [36]. There-
fore, calcineurin activity was assayed in this study. It 
was observed that simvastatin treatment suppressed 
the increase in subepicardial myocardium calcineurin 
activity in the AAB group. No differences in suben-
docardial myocardium calcineurin activity  were de-
tected between the four groups (Fig. 9). 
 
 
 
Figure 7. Expression of Kv4.3 protein in NRVMs. Immunoreactivity for Kv4.3 (red) and cardiac α-actin (green) was assessed by im-
munofluorescence 24 h after AngII treatment. Blue staining represents DAPI-stained nuclei. Photographs are representative of nine 
cultures from more than three separate experiments.  Int. J. Biol. Sci. 2012, 8 
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Figure 8. Simvastatin participates in the regulation of Ito in NRVMs. Panels A and B, typical current traces of outward K+ in the control 
(Panel A) and AngII-treated (Panel B) groups. Panel C, Ito (peak current densities minus Isus) between the control and AngII-treated groups 
at voltages ranging from -40 to +60 mV. Panel D, average current density at +60 mV between the control and AngII-treated groups. Panel 
E, Ito of four experimental groups at voltages ranging from-40 to +60mV. Panel F, average current density at +60 mV in different groups. 
Data are expressed as the mean ± SEM, n = 10. * P<0.05 vs. Ctrl group; # P<0.05 vs. AngII group.  
 
 
 
Figure 9. Bar graphs showing calcineurin activity in the rat left ventricle. Data are expressed as the mean ± SEM, n = 3. *  P<0.05 vs. Sham 
of respective groups; # P<0.05 vs. AAB of respective groups. EPI, subepicardial myocardium; ENDO, subendocardial myocardium. Int. J. Biol. Sci. 2012, 8 
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Discussion 
In this study, the main findings were as follows: 
1) rats exhibited significant left ventricular hypertro-
phy  seven  weeks  after  AAB,  which  was  associated 
with a clear decrease in Kv4.3 expression in suben-
docardial and subepicardial myocardium  of the left 
ventricle; 2) simvastatin partially reversed the down-
regulation in Kv4.3 expression in subepicardial myo-
cardium but not in subendocardial myocardium and 
was  associated  with  inhibition  of  cardiac  hypertro-
phy; and 3) simvastatin partially alleviated the AngII 
induced hypertrophy, Kv4.3 downregulation and Ito 
current reduction in NRVMs. Therefore, it is hypoth-
esized that simvastatin modulates Ito currents by reg-
ulating  Kv4.3  expression  in  hypertrophied  cardio-
myocytes.  
 Left ventricular hypertrophy (LVH) in response 
to elevated systemic pressure forms an adaptive and 
reversible mechanism that allows the heart to main-
tain cardiac output in the face of external stress [2, 36, 
37]. However, a large number of studies demonstrate 
that patients suffering from LVH have a greater risk 
of  cardiac  failure  compared  with  normotensive  pa-
tients and left ventricular regression is clearly associ-
ated with a reduction in the risk of adverse cardio-
vascular events [38-42]. LVH is also the most common 
cardiac manifestation followed by arrhythmias. It has 
been reported recently that hypertrophy is associated 
with significant repolarization delays and  increased 
mechanical function in a rat model of pressure over-
load  hypertrophy.  Furthermore,  the  pressure  over-
load  hypertrophy  secondary  to  aortic  constriction 
promotes the incidence of arrhythmias [2].  
In this study, the AAB model was used to gen-
erate LVH [43], which is characterized by increased 
LVWI, LVPWTd, IVSTd and ANP mRNA expression 
in the left ventricle. ANP is used as a marker of car-
diac hypertrophy due to its expression in cardiac hy-
pertrophy rather than in normal adult myocardium 
[33]. Furthermore, in the  present study, simvastatin 
suppression of LVH has been shown in AAB rats. This 
study showed that Kv4.3 expression was reduced in 
AAB rats and that this effect was partially reversed by 
simvastatin,  predominantly  in  subepicardial  myo-
cytes. Interestingly, this reduction in Kv4.3 expression 
levels was contradictory to a report that demonstrated 
that  Kv4.3  mRNA  but  not  protein  expression  was 
significantly  reduced  in  aldosterone-induced  hyper-
trophy  [1].  Thus,  although  some  responses  to  AAB 
mimic the response  of pathological stimuli, such as 
hypertrophy  and  electrical  remodeling,  differences 
are observed in the signaling pathways and eventual 
outcomes  of  physiological  and  pathological  stimuli 
[44].  These  so-called  complexities  may  reflect  that 
diverse mechanisms underlie the modulation of Kv4.3 
in different animal models. 
Total  Kv4.3  protein  levels  are  not  always  con-
sistent with Ito currents. Therefore, in order to assess 
the  regulatory  effect  of  simvastatin  on  the  electro-
physiological profile of cardiomyocytes, the Ito density 
in  single  cardiomyocytes  under  whole-cell 
patch-clamp conditions was investigated and immu-
nofluorescence staining was used to assess Kv4.3 ex-
pression in the cytolemma (Fig. 7 and 8). In accord-
ance with previous reports [44-46], this study showed 
that  Ito  density  was  reduced  in  response  to  hyper-
trophic stimuli. A reduction in membrane Kv4.3 ex-
pression was also observed in hypertrophied NRVMs 
and simvastatin partially reversed the reduction in Ito 
density and Kv4.3 expression. Simvastatin alone did 
not alter Ito density and Kv4.3 expression in AngII-free 
cells.  Kv4.3  is  the  tetraethylammonium  chlo-
ride-sensitive  cardiac  transient  outward  current  Ito 
subunit. Ito mediates phase I repolarization in cardiac 
action  potential  (AP)  and  influences  the  overall  AP 
configuration and duration [32]. Moreover, mice that 
are devoid of ventricular Ito are highly susceptible to 
arrhythmias  [47].  It  can  be  speculated  that  reduced 
Kv4.3 expression contributes to reduced Ito currents 
and loss of the repolarization in the cardiac AP, mak-
ing  Ca2+  release  in  ventricular  myocytes  less  syn-
chronous and resulting in increased susceptibility to 
cardiac  arrhythmias [48]. These results implied that 
Kv4.3  acts  as  a  potential  substrate  that  renders  the 
heart susceptible to arrhythmias. Thus, the results of 
this  study  indicate  that  simvastatin  may  alter  elec-
trophysiology in the pathological situation, partially 
through its effect on Kv4.3. The data obtained in this 
study  demonstrate  the  effects  of  simvastatin  treat-
ment on Ito levels and Kv4.3 expression and provide 
support  for  the  existence  of  cross-talk  between 
simvastatin  and  electrical  remodeling.  Furthermore, 
these data suggest that the anti-arrhythmia effect of 
simvastatin in cardiac hypertrophy may be associated 
with its effects on Ito, which are predominantly medi-
ated by Kv4.3. 
However, the mechanism underling the simvas-
tatin-mediated effects on Kv4.3 expression and Ito in 
cardiac  hypertrophy  is  complex.  Previous  studies 
have shown the Kv4.3 mRNA reduction observed in 
hypertrophy results from mRNA destabilization [15]. 
Furthermore,  studies  have  shown  that  statins  (in-
cluding simvastatin) reduce mRNA destabilization in 
several situations [49-52] and it is hypothesized that 
this is the mechanism responsible for the alleviation in 
Kv4.3  expression  reduction  observed  in  simvas-
tatin-treated hypertrophied rats. It has also been re-Int. J. Biol. Sci. 2012, 8 
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ported  that  the  potassium  channel  antagonist, 
4-aminopyridine,  enhanced  the  activation  of  extra-
cellular  signal-regulated  kinases  (ERK)  [53],  which 
phosphorylate  the  Kv  channel  subunit  [54-56],  re-
sulting in a reduced current [57]. Previous study has 
shown that simvastatin suppressed ERK phosphory-
lation  and  inhibited  AngII  induced  cardiomyocyte 
hypertrophy  [30],  indicating  that  simvastatin  may 
alleviate Ito reduction by suppressing ERK phosphor-
ylation,  resulting  in  alteration  in  the  biophysical 
properties  of  these  channels.  However,  Ren  et  al. 
showed that reduced expression of Kv channels pro-
teins is accompanied by reduced phosphorylation of 
extracellular ERK [58]. These contradictory observa-
tions  may  be  attributed  to  different  experimental 
conditions.  Furthermore,  Martins  et  al.  [59]  demon-
strated increased rat heart alkaline phosphatase (ALP) 
activity in response to statins in vitro. Therefore, it can 
be hypothesized that statin-mediated dephosphoryla-
tion of Kv channels in cardiomyocytes occurs through 
regulation  of  alkaline  phosphatase  activity.  Thus, 
simvastatin  may  also  increase  alkaline  phosphatase 
activity, resulting in Kv channel dephosphorylation, 
which are in turn, related to the beneficial effects of 
simvastatin. However, further studies are required to 
determine the putative effects of statins on ALP ac-
tivity in the cardiac tissue.  
It should be noted that the reversal in the reduc-
tion in Kv4.3 expression was observed in the subepi-
cardial myocardium but not the subendocardial my-
ocardium in simvastatin-treated rats showed in this 
study. It has been well documented that Kv4.2 mRNA 
expression varies across the ventricular wall of the rat 
and  Kv4.2  protein  expression  parallels  the  regional 
heterogeneity in Ito density, while Kv4.3 is expressed 
at  equivalent  levels  across  the  ventricular  wall  [60, 
12]. However, different potassium channel  subunits 
have been shown to be responsible for the cardiac Ito 
in higher mammalian species compared with the ro-
dent  [12].  It  has  been  reported  that  Kv4.3,  as  the 
pore-forming subunit, appears to be solely responsi-
ble for Ito in canine and human heart [61, 62]. Thus, 
since the distribution of Kv4.3 across the ventricle is 
homogeneous,  blockade  of  this  channel  by  specific 
drugs may not alter the normal heterogeneity of  Ito 
current [63]. In our study, with the exception of the 
AABS group there were no significant differences in 
Kv4.3  expression  between  the  subendocardial  and 
subepicardial myocardium in the sham, SS and AAB 
groups.  Compared  with  the  AAB  group,  the  AABS 
group exhibited significantly higher Kv4.3 expression 
in  subepicardial  myocardium.  These  data  strongly 
support  the  hypothesis  that  simvastatin  altered 
transmural Kv4.3 expression and may modulate the 
electrophysiology in hypertrophied heart. 
In this study, it was demonstrated that calcineu-
rin activity in subepicardial myocardium was lower 
than that in subendocardial myocardium in the sham 
and SS groups. Furthermore, the calcineurin activity 
was increased in subepicardium myocardium in the 
AAB group. These data are consistent with the pre-
vious  reports  [64,  65].  Furthermore,  in  the  AABS 
group, calcineurin activity was partially reversed by 
simvastatin  in  subepicardial  myocardium.  This  was 
accompanied  by  recovery  of  transmural  Kv4.3  ex-
pression  in  the  AABS  group.  However,  it  has  been 
reported that simvastatin induced PC3 prostate can-
cer cell necrosis is mediated by calcineurin [66]. Thus, 
although it is speculated that calcineurin is involved 
in the simvastatin induced recovery of Kv4.3, the ef-
fects of simvastatin on calcineurin activity remain to 
be  elucidated  and  experimental  discrepancies  may 
result  from  differences  in  experimental  conditions 
and cells.  
In  summary,  this  study  demonstrated  that 
simvastatin modulated Kv4.3 expression and Ito cur-
rents in hypertrophied rat hearts. However, it should 
be noted that interpretation of these results is subject 
to a number of limitations. Firstly, these results are 
applicable only to rats due to species differences in 
Kv4.3 expression and confirmation of similar changes 
in  human  hypertrophied  cardiomyocytes  requires 
further  investigation.  Secondly,  although  the  Kv4.3 
expression  reported  here  are  from  the  two  extreme 
surfaces of the left ventricular myocardium, it should 
be noted that the small size of the rat left ventricle 
may have resulted in inaccuracies in tissue sampling 
defined  as”  subepicardial”  and  “subendocardial” 
myocardium,  which  might  have  significantly  influ-
enced  the  results.  Thirdly,  due  to  the  limitation  of 
research conditions, monophasic APs were not tested 
in  the  whole  heart.  Furthermore,  in  this  study,  ex-
pression of another Ito alpha subunit, Kv4.2, was not 
investigated due to the lack of availability of a specif-
ically reactive detection antibody. Therefore, although 
Kv4.3 and Ito may contribute to repolarization of the 
early plateau phase in that even small currents can 
have  significant  effects  on  the  balance  of  currents 
during  the  plateau  of  the  AP,  there  are  numerous 
other ion channels and currents known to be active in 
the whole heart. Thus, the effect of simvastatin on the 
electrophysiologic parameters of the whole heart and 
the surface ECG on the development of pathological 
electrical stimulation requires further investigation.  
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